Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Vaccines

  Free Subscription


25.03.2024

2 Ann Intern Med
2 BMJ
2 J Infect
3 J Infect Dis
4 J Virol
2 JAMA
3 N Engl J Med
3 Pediatr Infect Dis J
1 PLoS Med
12 PLoS One
29 Vaccine
1 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Intern Med

  1. HUITS R, Grubaugh ND, Libman M, Hamer DH, et al
    Resurgence of Dengue in the Era of Genomic Surveillance and Vaccines.
    Ann Intern Med. 2024 Mar 19. doi: 10.7326/M24-0496.
    PubMed        

  2. JOHANSEN ND, Vaduganathan M, Bhatt AS, Lee SG, et al
    Clinical Outcomes With Electronic Nudges to Increase Influenza Vaccination : A Prespecified Analysis of a Nationwide, Pragmatic, Registry-Based, Randomized Implementation Trial.
    Ann Intern Med. 2024 Mar 19. doi: 10.7326/M23-2638.
    PubMed         Abstract available


    BMJ

  3. WISE J
    RSV: Paediatricians call on government to expedite infant vaccination programme.
    BMJ. 2024;384:q706.
    PubMed        

  4. LEEDOM M
    How climate change is changing vaccination planning.
    BMJ. 2024;384:q360.
    PubMed        


    J Infect

  5. SALMAN M, Rana MS, Usman M, Tahir M, et al
    Re-emergence of Diphtheria after COVID-19 Pandemic in Pakistan: time to consider booster vaccination strategies.
    J Infect. 2024 Mar 19:106141. doi: 10.1016/j.jinf.2024.106141.
    PubMed        

  6. SUN L, Man Q, Zhang H, Xia S, et al
    Strong cross immune responses against sarbecoviruses but not merbecoviruses in SARS-CoV-2 BA.5/BF.7-infected individuals with or without inactivated COVID-19 vaccination.
    J Infect. 2024;88:106138.
    PubMed        


    J Infect Dis

  7. FIGUEROA AL, Azzi JR, Eghtesad B, Priddy F, et al
    Safety and Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Solid Organ Transplant Recipients.
    J Infect Dis. 2024 Mar 21:jiae140. doi: 10.1093.
    PubMed         Abstract available

  8. PRUNAS O, Shioda K, Toscano CM, Bastias M, et al
    Estimated population-level impact of pneumococcal conjugate vaccines against all-cause pneumonia mortality among unvaccinated age groups in five Latin American countries.
    J Infect Dis. 2024 Mar 19:jiae144. doi: 10.1093.
    PubMed         Abstract available

  9. KING LM, Andrejko KL, Kabbani S, Tartof SY, et al
    Outpatient visits and antibiotic use due to higher valency pneumococcal vaccine serotypes.
    J Infect Dis. 2024 Mar 18:jiae142. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  10. NUNBERG JH, Westover JB, York J, Jung KH, et al
    Restoration of virulence in the attenuated Candid#1 vaccine virus requires reversion at both positions 168 and 427 in the envelope glycoprotein GPC.
    J Virol. 2024 Mar 20:e0011224. doi: 10.1128/jvi.00112.
    PubMed         Abstract available

  11. MAI F, Bergmann W, Reisinger EC, Muller-Hilke B, et al
    The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection.
    J Virol. 2024 Mar 19:e0191223. doi: 10.1128/jvi.01912.
    PubMed         Abstract available

  12. KATAYAMA M, Murakami S, Ishida H, Matsugo H, et al
    Antigenic commonality and divergence of hemagglutinin-esterase-fusion protein among influenza D virus lineages revealed using epitope mapping.
    J Virol. 2024 Feb 12:e0190823. doi: 10.1128/jvi.01908.
    PubMed         Abstract available

  13. LI H, Sun H, Tao M, Han Q, et al
    Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.
    J Virol. 2024 Feb 2:e0112923. doi: 10.1128/jvi.01129.
    PubMed         Abstract available


    JAMA

  14. EDWARDS KM, Griffin MR
    Postmarketing Vaccine Safety Assessments: Important Work in Progress.
    JAMA. 2024;331:915-917.
    PubMed        

  15. LU Y, Matuska K, Nadimpalli G, Ma Y, et al
    Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults.
    JAMA. 2024;331:938-950.
    PubMed         Abstract available


    N Engl J Med

  16. HAVIARI S, Massonnaud CR, Dupont A
    Recombinant Influenza Vaccine in Adults under 65 Years of Age.
    N Engl J Med. 2024;390:1155.
    PubMed        

  17. WOO EJ, Hulse AN
    Recombinant Influenza Vaccine in Adults under 65 Years of Age.
    N Engl J Med. 2024;390:1155-1156.
    PubMed        

  18. HSIAO A, Fireman B, Klein NP
    Recombinant Influenza Vaccine in Adults under 65 Years of Age. Reply.
    N Engl J Med. 2024;390:1156.
    PubMed        


    Pediatr Infect Dis J

  19. PLOTKIN SA, Offit P
    Efficacy of Rotavirus Vaccines.
    Pediatr Infect Dis J. 2024 Mar 20. doi: 10.1097/INF.0000000000004319.
    PubMed        

  20. MEYER J, Silas P, Ouedraogo GL, McElwee K, et al
    A Phase 3, Single-Arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of Age.
    Pediatr Infect Dis J. 2024 Mar 15. doi: 10.1097/INF.0000000000004318.
    PubMed         Abstract available

  21. MAROM T, Ovnat Tamir S
    Pediatric Otitis Media in the New Pneumococcal Conjugate Vaccines Era: What's Next?
    Pediatr Infect Dis J. 2024 Mar 15. doi: 10.1097/INF.0000000000004323.
    PubMed        


    PLoS Med

  22. MOODIE Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, et al
    Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
    PLoS Med. 2024;21:e1004360.
    PubMed         Abstract available


    PLoS One

  23. WALSH-BUHI ML, Houghton RF, Valdez D, Walsh-Buhi ER, et al
    A theory-based assessment of mpox: Findings from a nationally representative survey of U.S. adults.
    PLoS One. 2024;19:e0299599.
    PubMed         Abstract available

  24. STOSIC M, Plavsa D, Jovanovic V, Veljkovic M, et al
    Factors associated with COVID-19 among hospitalized patients with severe acute respiratory infections in Serbia, 2022-2023: A test negative case-control study.
    PLoS One. 2024;19:e0299210.
    PubMed         Abstract available

  25. UMER BA, Noyce RS, Kieser Q, Favis NA, et al
    Oncolytic vaccinia virus immunotherapy antagonizes image-guided radiotherapy in mouse mammary tumor models.
    PLoS One. 2024;19:e0298437.
    PubMed         Abstract available

  26. TRZEBINSKI W, Trzebinski J
    How does collectivism help deal with perceived vaccine artificiality? The case of COVID-19 vaccination intent in European young adults.
    PLoS One. 2024;19:e0300814.
    PubMed         Abstract available

  27. KOSKAN A, Larkey L, Todd M, Kim SW, et al
    Protocol for a community-based digital storytelling pilot intervention to reduce Hispanic parents' vaccine hesitancy to immunize their children against COVID-19.
    PLoS One. 2024;19:e0299787.
    PubMed         Abstract available

  28. ZHENG D, Sun Q, Su Z, Kong F, et al
    Correction: Enhancing Specific-Antibody Production to the ragB Vaccine with GITRL That Expand Tfh, IFN-gamma+ T Cells and Attenuates Porphyromonas gingivalis Infection in Mice.
    PLoS One. 2024;19:e0301151.
    PubMed         Abstract available

  29. GUERRERIO AL, Mateja A, MacCarrick G, Fintzi J, et al
    Web-based survey investigating cardiovascular complications in hypermobile Ehlers-Danlos syndrome after COVID-19 infection and vaccination.
    PLoS One. 2024;19:e0298272.
    PubMed         Abstract available

  30. LANZA-LEON P, Cantarero-Prieto D, Pascual-Saez M
    Exploring trends and determinants of basic childhood vaccination coverage: Empirical evidence over 41 years.
    PLoS One. 2024;19:e0300404.
    PubMed         Abstract available

  31. LI Y, Li J, He J, Tao C, et al
    AE-GPT: Using Large Language Models to extract adverse events from surveillance reports-A use case with influenza vaccine adverse events.
    PLoS One. 2024;19:e0300919.
    PubMed         Abstract available

  32. LEE DH, Lee SH, Kim AR, Quan FS, et al
    Correction: Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii.
    PLoS One. 2024;19:e0301214.
    PubMed         Abstract available

  33. TOWNSLEY H, Gahir J, Russell TW, Greenwood D, et al
    COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.
    PLoS One. 2024;19:e0294897.
    PubMed         Abstract available

  34. LEE KS, Go MJ, Choi YY, Kim MK, et al
    Risk factors for critical COVID-19 illness during Delta- and Omicron-predominant period in Korea; using K-COV-N cohort in the National health insurance service.
    PLoS One. 2024;19:e0300306.
    PubMed         Abstract available


    Vaccine

  35. MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al
    Differences in social media use by COVID-19 vaccination status.
    Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  36. SASI A, Dandotiya J, Kaushal J, Ganguly S, et al
    Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  37. BROOKS SP, Sidhu K, Cooper E, Michelle Driedger S, et al
    The influence of health service interactions and local policies on vaccination decision-making in immigrant women: A multi-site Canadian qualitative study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00299-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  38. CRISTINA MARTINI RODRIGUES C, Caroline Ribeiro Sales A, Marli Christovam Sartori A, de Souza Azevedo A, et al
    Yellow fever neutralizing antibody seroprevalence proportion and titers in previously vaccinated adults with chronic kidney disease.
    Vaccine. 2024 Mar 20:S0264-410X(24)00316-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  39. ARTIGAS-JERONIMO S, Villar M, Estrada-Pena A, Alberdi P, et al
    Subolesin knockdown in tick cells provides insights into vaccine protective mechanisms.
    Vaccine. 2024 Mar 19:S0264-410X(24)00278-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  40. CHENG Y, Shen R, Liu F, Li Y, et al
    Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines.
    Vaccine. 2024 Mar 19:S0264-410X(24)00326-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  41. KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al
    Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity.
    Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  42. GEHRT L, Englund H, Laake I, Nieminen H, et al
    Is vaccination against measles, mumps, and rubella associated with reduced rates of antibiotic treatments among children below the age of 2 years? Nationwide register-based study from Denmark, Finland, Norway, and Sweden.
    Vaccine. 2024 Mar 19:S0264-410X(24)00313-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  43. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al
    CHO cells for virus-like particle and subunit vaccine manufacturing.
    Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  44. WU J, Jiang L, Shao Q, Liu J, et al
    Comparison of the safety and efficacy of the wild-type and lpxL/lpxM mutant inactivated vaccine against the avian pathogenic Escherichia coli O1, O2, and O78 challenge.
    Vaccine. 2024 Mar 18:S0264-410X(24)00325-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  45. MEDENI V, Altiner OT, Medeni I
    Measles vaccination coverage and immunization status of nurses: An interventional study in Turkiye.
    Vaccine. 2024 Mar 18:S0264-410X(24)00324-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  46. DANGOR Z, Benson N, Berkley JA, Bielicki J, et al
    Vaccine value profile for Klebsiella pneumoniae.
    Vaccine. 2024 Mar 18:S0264-410X(24)00248-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  47. OPMEER L, Gazzoli I, Ballmann M, Willemsen M, et al
    High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains.
    Vaccine. 2024 Mar 18:S0264-410X(24)00130-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  48. MULLER T, Wallace RM, Freuling CM
    Rabies importation in dogs and reduction of waiting period - The fear for scientifically justified changes.
    Vaccine. 2023 Oct 20:S0264-410X(23)01043-5. doi: 10.1016/j.vaccine.2023.
    PubMed        

  49. HYAMS C, Lahuerta M, Theilacker C, King J, et al
    Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UK.
    Vaccine. 2024;42:1599-1607.
    PubMed         Abstract available

  50. ZIBOLENOVA J, Malobicka E, Ulbrichtova R, Novak M, et al
    Probability of exposure to the wild measles virus in adult population - Estimation from seroepidemiology and historical data.
    Vaccine. 2024;42:1648-1655.
    PubMed         Abstract available

  51. KWON KW, Choi HG, Choi HH, Choi E, et al
    Immunogenicity and protective efficacy of RipA, a peptidoglycan hydrolase, against Mycobacterium tuberculosis Beijing outbreak strains.
    Vaccine. 2024;42:1941-1952.
    PubMed         Abstract available

  52. KOCHHAR S, Assis DN, Mack C, Izurieta HS, et al
    Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Feb 16:S0264-410X(24)00021-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  53. SOVIK WLM, Madsen AMR, Aaby P, Nielsen S, et al
    The association between BCG scars and self-reported chronic diseases: A cross-sectional observational study within an RCT of Danish health care workers.
    Vaccine. 2024;42:1966-1972.
    PubMed         Abstract available

  54. LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al
    Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.
    Vaccine. 2024;42:2004-2010.
    PubMed         Abstract available

  55. ANWARI P, Burnett E, Chavers TP, Samsor A, et al
    Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018-2022.
    Vaccine. 2024;42:2059-2064.
    PubMed         Abstract available

  56. MACKENZIE GA, Hossain I, Salaudeen R, Badji H, et al
    Impact of pneumococcal conjugate vaccination on pneumococcal nasopharyngeal carriage in the Gambia: Population-based cross-sectional surveys.
    Vaccine. 2024 Mar 14:S0264-410X(24)00225-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  57. CAMERON DB, Grage L, Van Wyck R, Edwards A, et al
    Identifying trusted local sources and predicting behavior change pathways according to COVID-19 vaccination status: Results of a 2022 statewide survey of Alaskan adults.
    Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  58. JUNEAU C, Fall E, Bros J, Le Duc-Banaszuk AS, et al
    Do boys have the same intentions to get the HPV vaccine as girls? Knowledge, attitudes, and intentions in France.
    Vaccine. 2024 Mar 14:S0264-410X(24)00256-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  59. COTTON SA, Subramanian A, Hughes TD, Huang Y, et al
    The effect of SARS-COV-2 variant on non-respiratory features and mortality among vaccinated and non-fully vaccinated patients.
    Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  60. FIX J, Christopher Mast T, Smith K, Baker N, et al
    Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
    Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  61. HARTMEIER PR, Ostrowski SM, Busch EE, Empey KM, et al
    Lymphatic distribution considerations for subunit vaccine design and development.
    Vaccine. 2024 Mar 16:S0264-410X(24)00320-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  62. FIERRO C, Weidenthaler H, Vidojkovic S, Schmidt D, et al
    Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial.
    Vaccine. 2024 Mar 16:S0264-410X(24)00296-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  63. CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al
    COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
    Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available


    Virology

  64. AMOSOVA IV, Timoshicheva TA, Kadyrova RA, Zabrodskaya YA, et al
    The investigation of the dynamics of changes in neutralizing antibody titers against type 5 adenovirus in the context of vaccination against a new coronavirus infection.
    Virology. 2024;594:110051.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.